Search

ENANTA PHARMACEUTICALS INC

Geschlossen

BrancheGesundheitswesen

13.14 -2.45

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12.92

Max

13.45

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.2M

-13M

Verkäufe

-2.8M

14M

EPS

-0.67

Gewinnspanne

-76.292

Angestellte

120

EBITDA

-30M

-39M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+48.81% upside

Dividenden

By Acuity

Nächstes Ergebnis

13. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-22M

400M

Vorheriger Eröffnungskurs

15.59

Vorheriger Schlusskurs

13.14

Nachrichtenstimmung

By Acuity

75%

25%

317 / 340 Ranking in Healthcare

ENANTA PHARMACEUTICALS INC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Aug. 2026, 20:06 UTC

Enanta Pharmaceuticals is trading lower amid mixed market sentiment following a reported decline in U.S. retail sales for July.

13. Aug. 2026, 19:36 UTC

Enanta Pharmaceuticals Inc is trading higher, remaining above its 20-day moving average, despite no specific company news identified for the price movement.

11. Aug. 2026, 20:06 UTC

Enanta Pharmaceuticals Inc shares are lower today, reflecting broader market declines. The stock reached a session low earlier but has since recovered slightly.

5. Aug. 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower, reflecting broader market sentiment amid disappointing ADP employment data showing a rise of only 44,000 jobs in July.

4. Aug. 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are higher, buoyed by a decline in crude oil prices that eases inflation concerns. No specific company news was identified.

3. Aug. 2026, 19:23 UTC

Enanta Pharmaceuticals Inc shares are rising amid a broader market rally, supported by gains in major technology stocks and renewed investor confidence.

31. Juli 2026, 20:06 UTC

Enanta Pharmaceuticals Inc's shares are lower today, continuing a downward trend amid rising U.S. Treasury yields and crude oil prices. No specific news was identified.

30. Juli 2026, 19:45 UTC

Enanta Pharmaceuticals Inc. is advancing, supported by broader market gains. Earlier in the session, shares pulled back from a session high.

29. Juli 2026, 18:26 UTC

Enanta Pharmaceuticals Inc is declining in Wednesday's session, marking the seventh consecutive day of lower prices. No specific news has been identified to explain the movement.

28. Juli 2026, 20:06 UTC

Enanta Pharmaceuticals Inc is declining, marking five consecutive sessions lower. The stock peaked earlier but has since pulled back amid broader market pressures.

27. Juli 2026, 18:36 UTC

Enanta Pharmaceuticals Inc is higher today, building on Friday's momentum amid broader market dynamics following a decline in oil prices.

24. Juli 2026, 20:06 UTC

Enanta Pharmaceuticals Inc. shares are lower today, reversing from a recent trend of higher daily closes since Thursday's close.

21. Juli 2026, 19:31 UTC

Enanta Pharmaceuticals is rising during Tuesday's session, reflecting broader market strength and positive sentiment from recent earnings reports by General Motors and Novartis.

20. Juli 2026, 19:46 UTC

Enanta Pharmaceuticals Inc shares are lower today, continuing a decline since Friday's close. The stock has shown significant volatility during the session.

Peer-Vergleich

Kursveränderung

ENANTA PHARMACEUTICALS INC Prognose

Kursziel

By TipRanks

48.81% Vorteil

12-Monats-Prognose

Durchschnitt 20 USD  48.81%

Hoch 20 USD

Tief 20 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ENANTA PHARMACEUTICALS INC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Stimmung

By Acuity

317 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
help-icon Live chat